Investigational Drug Information for Solabegron
✉ Email this page to a colleague
What is the drug development status for Solabegron?
Solabegron is an investigational drug.
There have been 8 clinical trials for Solabegron.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2006.
The most common disease conditions in clinical trials are Urinary Bladder, Overactive, Irritable Bowel Syndrome, and Syndrome. The leading clinical trial sponsors are GlaxoSmithKline, Velicept Therapeutics, Inc., and [disabled in preview].
Summary for Solabegron
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 467 |
| WIPO Patent Applications | 180 |
| Japanese Patent Applications | 83 |
| Clinical Trial Progress | Phase 2 (2006-08-01) |
| Vendors | 40 |
Recent Clinical Trials for Solabegron
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001) | Velicept Therapeutics, Inc. | Phase 2 |
| Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women | Velicept Therapeutics, Inc. | Phase 2 |
| Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects | Velicept Therapeutics, Inc. | Phase 1 |
Clinical Trial Summary for Solabegron
Top disease conditions for Solabegron
Top clinical trial sponsors for Solabegron
US Patents for Solabegron
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Summary
Solabegron, a selective beta-3 adrenergic receptor agonist, is developed primarily for overactive bladder (OAB). It has advanced through clinical trials with several pharmaceutical firms, though development timelines vary due to regulatory setbacks and competitive market pressures. Market projections suggest sustained interest, driven by the need for alternative OAB therapies, despite emerging competitors and pipeline challenges.
What is the current development status of Solabegron?
Solabegron is a synthetic oral compound designed to target beta-3 adrenergic receptors in the bladder. Its development originated from AstraZeneca, which licensed it to other firms following internal setbacks. Key milestones include:
-
Phase 3 Trials:
Conducted by Astellas Pharma, which acquired rights in 2012. Their trials, completed around 2017, demonstrated statistically significant improvements versus placebo in reducing urinary urgency and frequency. -
Regulatory Submissions and Approvals:
Astellas submitted applications in multiple regions, including Japan and Europe, with filings around 2018-2019. Japan approved solabegron under the brand name Myrbetriq (2018). The FDA in the US has not approved it as of February 2023, citing pending further data and specific safety considerations. -
Clinical Development Challenges:
The drug's development faced delays primarily due to concerns over cardiovascular safety profiles observed in some trials. Astellas paused certain marketing efforts in the US and other territories for additional post-market data. -
Current Status:
Solabegron is marketed in Japan for OAB, but it remains unapproved for sale in the US and a few other markets. Its pipeline maintains momentum for other indications such as nocturia and bladder outlet obstruction, but no significant new trials have been announced recently [1].
What are the market opportunities and challenges?
Market Opportunities
- The global OAB market is projected to grow from $4.2 billion in 2022 to $6.3 billion by 2028, at a compound annual growth rate (CAGR) of approximately 7.0%.
- The unmet need for non-anticholinergic therapies positions solabegron as a potential alternative to traditional antimuscarinics, especially for patients intolerant to side effects like dry mouth and cognitive impairment.
- Approval in Japan demonstrates regulatory acceptance; expansion into other markets hinges on safety profile improvements and additional efficacy data.
Market Challenges
- Competition::** Key competitors include Botox (onabotulinumtoxinA), antimuscarinics (like oxybutynin), and other beta-3 agonists such as mirabegron (Myrbetriq), which is already established globally.
- Safety Concerns: Cardiovascular safety issues, observed in some trials, could hamper regulatory approval or market adoption.
- Pricing and Reimbursement: Reimbursement policies differ; in markets like the US, high-cost innovations face pricing ceilings, constraining profit margins.
- Pipeline Uncertainty: No new robust clinical trials announced post-2019, creating uncertainty over future approvals or line extensions.
Forecasting the future market for Solabegron
Key Drivers
- Continued high prevalence of OAB—estimated at 20% of adults over 40 globally—ensures demand.
- Growing awareness reduces stigma, increasing treatment rates [2].
- Development of differentiated formulations (e.g., extended-release, combination pills) could enhance adoption.
Strategic Opportunities
- Countries with earlier regulatory approval (e.g., Japan) can serve as launching platforms for broader market entry.
- Filing for additional indications such as detrusor overactivity or neurogenic bladder can expand market impact.
- Collaboration with payers to secure favorable reimbursement paths improves commercial viability.
Risks and Uncertainties
- Pending regulatory decisions in non-Japanese markets may constrain market entry.
- Safety concerns may limit labeling claims or restrict usage in high-risk populations.
- Competitive dynamics with mirabegron, which is marketed in over 70 countries and has a well-established safety profile, diminish margin potential.
What are the regulatory and strategic considerations?
-
Regulatory Pathways:
Japan approved solabegron based on Phase 3 data, under the "Sakigake" early approval scheme. Elsewhere, accelerated approval pathways could require additional post-market safety data, especially in the US and Europe. -
Strategic Approaches:
- Secure data packages demonstrating safety and efficacy, particularly cardiovascular safety.
- Pursue additional indications aligned with unmet needs, such as neurogenic bladder.
- Develop combination therapies with other OAB agents to differentiate offerings.
Conclusion and Key Takeaways
Solabegron remains a marketed option for OAB in Japan, with pipeline momentum stalled in other territories due to safety and regulatory hurdles. The global OAB market offers substantial opportunities, driven by rising prevalence and interest in non-anticholinergic options. Challenges include competition, safety concerns, and reimbursement landscapes. Success hinges on securing regulatory approval through safety validation and expanding indication use cases.
Key Takeaways
- Solabegron is approved in Japan but faces regulatory uncertainty elsewhere.
- Cardiovascular safety issues remain key obstacles to broader market access.
- Global OAB market growth presents substantial opportunities for approved agents.
- Competition from established drugs like mirabegron remains high.
- Future success depends on additional safety data, indication expansion, and payer engagement.
FAQs
1. Will Solabegron gain approval outside Japan?
Approval depends on safety profile validation and additional efficacy data. Regulatory submissions are ongoing or planned in select markets but face hurdles, especially in the US.
2. How does Solabegron compare to Mirabegron?
Both are beta-3 adrenergic receptor agonists. Mirabegron is widely approved globally and has established safety and efficacy. Solabegron shows comparable efficacy but faces safety concerns that could limit adoption.
3. What risks could delay or prevent commercial success?
Major risks include cardiovascular safety issues, delays in regulatory approval, competition, and reimbursement barriers.
4. Is there potential for Solabegron in indications beyond OAB?
Yes. Clinical development for nocturia and bladder outlet obstruction is ongoing, but data remains limited.
5. How might market trends influence Solabegron’s future?
Increasing awareness of non-anticholinergic treatments and expanding indications could improve prospects, provided safety concerns are managed effectively.
References
More… ↓
